The effect of dizocine on etomidate-propofol mixture EC50 for no-movement during gastroscopy in Different ages

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023875

Enrollment

Unknown

Registered

2019-06-15

Start date

2019-06-15

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

upper digestive tract disease

Interventions

ED group:50 µg/kg dezocine

ZD group:50 µg/kg dezocine

LD group:50 µg/kg dezocine

E group: etomidate-propofol mixture

Z group: etomidate-propofol mixture

L group:etomidate-propofol mixture

Eligibility

Sex/Gender

All

Age

6 Years to 85 Years

Inclusion criteria

Inclusion criteria: Informed consent was signed, aged 6-85 years, BMI 18.527.0 kg/m2, ASA I-II, gastroscopy, all patients had a clear awareness and fluent language in preoperative

Exclusion criteria

Exclusion criteria: Refuse to participate; Serious hepatic or renal dysfunction; Cardiovascular disease or dysfunction of blood coagulation; Related drug allergie; Obstructive sleep apnea hypopnea syndrome; BMI=28 kg/m2; history of alcoholism or psychotropic medication before gastroscopy.

Design outcomes

Primary

Measure	Time frame
Dose of the mixture of Etomidate and Propofol;	—

Secondary

Measure	Time frame
operation time;recovery time;the time of leaving PACU;Adverse reaction;	—

Countries

China

Contacts

Public ContactZhang Zhongqi

Shunde Hospital of Southern Medical University (the First People's Hospital of Shunde)

jxzzq11@139.com+86 13798682324

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026